What drugs to take long-term after heart attack

  The incidence of coronary heart disease and myocardial infarction has been increasing in recent years, and the treatment has become more and more standardized. However, some patients cannot adhere to the medication, and some doctors do not give patients standardized treatment, resulting in the aggravation of the patient’s condition after the infarction.  Here are some more information on which drugs need to be taken long-term after a heart attack, there are four main types of drugs that need to be taken long-term after an acute heart attack: Category I: anti-platelet aggregation drugs Such drugs are used to prevent thrombosis. Acute infarction of coronary heart disease is caused by the formation of thrombus in the coronary arteries blocking the coronary vessels. The purpose of long-term application of this drug is to prevent the formation of thrombus again.  Representative drugs in this category are enteric aspirin, clopidogrel, and tigretol. Most current guidelines recommend aspirin in combination with clopidogrel or in combination with tegretol for 1 year after acute infarction, followed by long-term aspirin, with or without coronary stenting.  Category 2: Cholesterol-lowering drugs These drugs are used to lower cholesterol. The increase of cholesterol content can easily cause coronary artery stenosis, and the increase of stenosis will further cause vessel occlusion, and then thrombosis will lead to heart attack. Therefore, these drugs are mainly used to treat the root cause of coronary heart disease.  The representative drugs of this kind are atorvastatin and resulvastatin. Warmly remind everyone that patients with coronary heart disease should take such drugs even if their cholesterol is not high.  The pharmacological effect of these drugs is to reduce myocardial oxygen consumption by slowing down the heart rate, antiarrhythmia, and improve post-infarction ventricular remodeling to improve cardiac function.  They are recommended for patients with acute anterior wall infarction because they are prone to ventricular prematureness, ventricular tachycardia, and even ventricular fibrillation during the acute phase of anterior wall infarction, and they are the most effective option for preventing and treating this condition. Acute inferior wall infarction is prone to slow arrhythmias during the acute phase, but when the patient recovers from slow arrhythmias or if no slow arrhythmias occur and the rhythm has stabilized, these drugs should also be used as early as possible.  The most commonly used of such drugs in clinical practice is betalactam, but it is advisable to apply betalactam extended-release tablets. Metoprolol succinate extended-release tablets. Use this drug with caution in the following three cases: patients with combined bronchial asthma, blood pressure below 90/60 mmHg, and heart rate below 60 beats per minute.  Class IV: ACEIorARB The Chinese name for the ACEl class of drugs is angiotensin-converting enzyme inhibitor, and studies have clearly shown that these drugs can help improve myocardial remodeling and reduce morbidity and mortality and heart failure.  ACEl drugs include captopril, enalapril, fosinopril, benazepril, ramipril, perindopril, etc. The common side effect of these drugs is dry cough. When dry cough occurs with the application of these drugs, the second best alternative to ACEl is ARB (angiotensin ll receptor antagonist), which has similar pharmacological effects to ACEl.  Many patients take these drugs as antihypertensive drugs and question their physicians about their application of this drug. The main effect of applying such drugs after a patient’s heart attack is not to lower blood pressure, but to improve the prognosis of the heart attack, even if the blood pressure is not high.  To take these four categories for a long time after a heart attack, patients may ask how long is long term, which is not clearly answered in the treatment guidelines. If an infarct patient is treated with reperfusion after onset, complete hemodynamic reconstruction, no post-infarction complications, controllable coronary risk factors have been controlled, no hypertension diabetes, and after three years of standardized treatment with these four classes of drugs, no cardiovascular events within three years, you can try to stop the drugs. However, most patients do not meet the above mentioned criteria, in which case they need to take medication for life.